← Companies
NOVAVAX INC
Data as of Oct 16, 2026
Reported federal lobbying
$1.9M
31 filings · latest Jul 17, 2026
Federal contracts since 2024
$15K
2 awards · latest Jun 2, 2024
Lobbying
$1,890,000 in reported federal lobbying spend across 31 quarterly filings, most recently Jul 17, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.
Spend by issue
- Health Issues$1.5M20 filings
- Medical/Disease Research/Clinical Labs$300K7 filings
- Health Issues +2$70K2 filings
Latest filings, Apr 2026 onward
| Filed | Registrant and subject | Amount |
|---|---|---|
| Jul 17, 2026 | NOVAVAX, INC for NOVAVAX INC Health Issues Issues related to federal vaccine programs and vaccine regulatory frameworks | $130,000 |
| Jul 16, 2026 | BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVAVAX INC. Health Issues Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 | $50,000 |
| Jul 15, 2026 | BALLARD PARTNERS for NOVAVAX INC. Medical/Disease Research/Clinical Labs Guidance navigating vaccine policy. | $50,000 |
| Apr 20, 2026 | NOVAVAX, INC for NOVAVAX INC Health Issues Issues related to COVID-19 vaccines, federal vaccine programs, and vaccine regulatory frameworks | $140,000 |
| Apr 16, 2026 | BALLARD PARTNERS for NOVAVAX INC. Medical/Disease Research/Clinical Labs Guidance navigating vaccine policy. | $50,000 |
| Apr 15, 2026 | BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVAVAX INC. Health Issues Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 | $50,000 |